Eduardo Arellano-Rodrigo, MD

Hematólogo de pura cepa. Hospital Clínic de Barcelona Inside
@hospitalclinic @hematoclinicbcn

#Thrombosis #Anticoagulation #MPN #MPNsm #GEMFIN

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

In #CALR-mutated #ET, high allele burden ≥ 35% was associated with a lower likelihood of achieving complete hematological response and with an increased risk of arterial thrombosis, progression to #myelofibrosis and death
#MPN #GEMFIN @Hemasphere_EHA
https://t.co/gzmIGUNcU9

[Carlos Fernandez de Larrea @fdezdelarrea]

Targeting BCMA: a double-edged sword for infection risk https://t.co/tKS4PpR1sm

[Blood Journals Portfolio @BloodPortfolio]

'Optical genome mapping in myelofibrosis: enhancing prognostic accuracy through high-resolution genomic profiling' read in Blood Advances: https://t.co/POjdkORkQo

[Blanca De Moner Rafel @blanca_demoner]

Circulating Cues Prime Endothelium in MPN-Related SVT. You can read the new article on our recently published manuscript here: https://t.co/lPBEyCkAfr

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

Proteomic profiling links complement activation to splanchnic vein thrombosis in JAK2V617F myeloproliferative neoplasms

@blanca_demoner @diaz_ricart #MPNsm @hematoclinicbcn @idibaps @UniBarcelona @CarrerasIJC

https://t.co/EZ5SLsdzDH

[Valentin Garcia #EHA2026 @jvalentingg]

📢 ¡Ya disponible la edición 2025 del Manual de Recomendaciones GEMFIN en Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas!
Una herramienta clave para la práctica clínica.
📘 Descárgalo aquí 👉 https://t.co/GlS9nW53nd
#GEMFIN #MPN #Hematología @sehh_es @HematoRYC

[Valentin Garcia #EHA2026 @jvalentingg]

🔴 Comienza nuestra IX Reunión Anual del grupo GEMFIN. Excelente programa educacional y revisión de proyectos en marcha. ¡Más de 160 asistentes! Un éxito de participación. @sehh_es #GEMFIN #Hematología #MPN

[Valentin Garcia #EHA2026 @jvalentingg]

Outstanding talk by Dr. William Vainchenker at the GEMFIN Annual Meeting:
“Twenty years since the discovery of JAK2 V617F. Molecular advances in MPNs since then.”
A privilege to learn from one of the pioneers in the field. #MPNs #JAK2 #Hematology #GEMFIN2025

[Valentin Garcia #EHA2026 @jvalentingg]

¡Recién salidas del horno! 📘 Presentamos en nuestra reunión anual las nuevas guías GEMFIN.
Esperamos que sean una herramienta de gran utilidad para todos los compañeros implicados en el manejo de las NMP. #GEMFIN2025 #NMP #Hematología @sehh_es

[Gonzalo Carreño Gómez-Tarragona @GonzaloHEM]

It's out!! I am thrill to share with you our new paper in @BloodJournal where we show that JAK2 46/1 haplotype regulates PD-L1 expression. This opens the door to new research lines and, who knows, future treatments for our MPN patients.

https://t.co/XT5GnfQKnx

[Valentin Garcia #EHA2026 @jvalentingg]

Our latest study from the GEMFIN group has just been published in Blood Cancer Journal!
We report real-world data on the efficacy and safety of momelotinib in patients with myelofibrosis: https://t.co/gW1vVmgFBb
@sehh_es

[Valentin Garcia #EHA2026 @jvalentingg]

📢Nos complace compartir que nuestros compañeros, @GonzaloHEM y JC Hernández-Boluda, han publicado dos artículos originales en la prestigiosa revista Blood.Gran logro de la Hematología española y GEMFIN. Enhorabuena a los autores! 👏 @sehh_es @mpnspain_

[Gabriela Ene @gabrielaene10]

Very happy to be part of this international collaboration 🇨🇦🇫🇷🇪🇸🇳🇿🇩🇪 defining the VITT-like Monoclonal Gammopathy of Thrombotic Significance ⁦⁦⁦@hospitalclinic⁩ https://t.co/vlrJ3HX9jx

[Mercedes Montoro @mercedesmontoro]

📢 La EPACAR-T evalúa mediante escalas validadas e identifica a los candidatos que pueden beneficiarse de soporte psicológico y social para mejorar su salud. https://t.co/DyYmYWaCzz @Crismar82 @enfClinica @hematoclinicbcn @hospitalclinic #Payora #CRamos #Ggarcia #ADomènech

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

@TH_Journal
https://t.co/o6eEItAi27

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

Circulating factors in JAK2V617F-mutated #MPN with splanchnic vein thrombosis induce endothelial proinflammatory and prothrombotic phenotypes, which are modulated by therapy
@blanca_demoner @martagarrote @BloodyMeri_Xell @jcgarciapagan @diaz_ricart
@hematoclinicbcn

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

@hematoclinicbcn #GEMFIN
#MPN @LeukemiaJnl
@martagarrote @Aliciasm84
@raularchena @paquiferrer_
@GonzaloHEM @AnnaAngona
@jvalentingg

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia: https://t.co/0BZPOA8uK2

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

High-risk patients achieving complete hematological response to first-line hydroxyurea showed a reduced risk of arterial thrombosis, a lower rate of progression to myelofibrosis and better survival: Data from Spanish Registry of ET

#MPN @LeukemiaJnl

https://t.co/KESJi8tCii

[Eduardo Arellano-Rodrigo, MD @ArellanoRodrig0]

High-risk patients achieving complete hematological response to first-line hydroxyurea showed a reduced risk of arterial thrombosis, a lower rate of progression to myelofibrosis and better survival: Data from Spanish Registry of ET

#MPN @LeukemiaJnl

https://t.co/KESJi8tCii